Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PST-611

Phase 2Biologic

PST-611 is one of 12 biologic programs targeting Geographic Atrophy. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyNot yet recruiting

Geographic AtrophyPhase 2

Not yet recruiting

Competition

Competitive Landscape

18 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Eylea

Izervay

Tecfidera

Farxiga

Tinlarebant

BBelite Bio, Inc

Vonaprument

Opregen

JNJ-81201887

Johnson & Johnson

BS01

BBionic Sight LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Geographic Atrophy

NCT07705568

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

An Open-label Multiple Dose Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Not yet recruiting·EEyevensys·Phase 2·NCT07705568·24 enrolled

Dry Age Related Macular Degeneration1 trial

An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration

Completed·EEyevensys·Phase 1·NCT07024732·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PST-611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PST-611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PST-611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eyevensys company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: EEyevensys

Related News